Portable and Battery-Powered PCR Device for DNA Amplification and Fluorescence Detection

Jie, Junyao; Hu, Shiming; Liu, Wenwen; Wei, Qingquan; Huang, Yanqun; Yuan, Xinxin; Ren, Lufeng; Tan, Manqing; Yu, Yude

doi:10.3390/s20092627

Cited by 23 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Miniaturization now also makes highly sensitive and selective and rapid analyte detection by a range of mass spectrometry protocols possible, even at the bedside ( 132 ). Even nucleic acid biomarkers can now be detected within minutes, with recent publications reporting completion of 30 qPCR cycles within 54 s ( 133 ), certainly fast enough for stroke diagnostics if the promise of portable devices that might be used at the bedside ( 134 ) are realized. Moreover, nanotechnology offers the promise of highly multiplexed biosensors capable of rapid simultaneous analysis of large panels of biomarkers ( 135 ), an important consideration if multiple analytes must be assessed to provide stroke diagnosis and prognosis.…”

Section: Discussionmentioning

confidence: 99%

Acute Stroke Biomarkers: Are We There Yet?

et al. 2021

View full text Add to dashboard Cite

Background: Distinguishing between stroke subtypes and knowing the time of stroke onset are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments in selected patients with acute ischemic stroke. Neuroimaging helps decide who should be treated and how they should be treated but is expensive, not always available and can have contraindications. These limitations contribute to the under use of these reperfusion therapies.Aim: An alternative approach in acute stroke diagnosis is to identify blood biomarkers which reflect the body's response to the damage caused by the different types of stroke. Specific blood biomarkers capable of differentiating ischemic from hemorrhagic stroke and mimics, identifying large vessel occlusion and capable of predicting stroke onset time would expedite diagnosis and increase eligibility for reperfusion therapies.Summary of Review: To date, measurements of candidate biomarkers have usually occurred beyond the time window for thrombolysis. Nevertheless, some candidate markers of brain tissue damage, particularly the highly abundant glial structural proteins like GFAP and S100β and the matrix protein MMP-9 offer promising results. Grouping of biomarkers in panels can offer additional specificity and sensitivity for ischemic stroke diagnosis. Unbiased “omics” approaches have great potential for biomarker identification because of greater gene, protein, and metabolite coverage but seem unlikely to be the detection methodology of choice because of their inherent cost.Conclusion: To date, despite the evolution of the techniques used in their evaluation, no individual candidate or multimarker panel has proven to have adequate performance for use in an acute clinical setting where decisions about an individual patient are being made. Timing of biomarker measurement, particularly early when decision making is most important, requires urgent and systematic study.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Stroke Biomarkers: Are We There Yet?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…During 2020, the improvement in biosensor technology has made this type of system emerge and improve significantly. 38,47,63 Although these devices will become useful for field veterinarians, there is still a need to improve the systems by better dealing with the various environmental conditions that swine veterinarians encounter in the field, such as highly variable temperatures, moisture, dust, biosecurity issues, availability of suitable facilities, sample processing, or the overall processing time from sample collection to result reading. Aside from the well-recognized and previously mentioned disadvantages of PCR, another issue is the inability to differentiate pathogenic strains of L. intracellularis from the live attenuated vaccine strain (Enterisol Ileitis; Boehringer Ingelheim Vetmedica).…”

Section: Molecular Detectionmentioning

confidence: 99%

“…During 2020, the improvement in biosensor technology has made this type of system emerge and improve significantly. 38 , 47 , 63 …”

Section: Molecular Detectionmentioning

confidence: 99%

Review of methods for the detection of Lawsonia intracellularis infection in pigs

et al. 2021

View full text Add to dashboard Cite

Lawsonia intracellularis is an obligate intracellular bacterium associated with enteric disease in pigs. Clinical signs include weight loss, diarrhea, and, in some cases, sudden death. The hallmark lesion is the thickening of the intestinal mucosa caused by increased epithelial cell replication, known as proliferative enteropathy. The immune response to L. intracellularis is not well defined, and detection of the infection, especially in the early stages, is still a significant challenge. We review here the main approaches used to identify this important but poorly understood pathogen. Detection of L. intracellularis infection as the cause of clinical disease is confounded by the high prevalence of the pathogen in many countries and that several other pathogens can produce similar clinical signs. A single L. intracellularis–specific ELISA and several amplification assays are available commercially to aid detection and surveillance, although histopathology remains the primary way to reach a conclusive diagnosis. There are major gaps in our understanding of L. intracellularis pathogenesis, especially how the host responds to infection and the factors that drive infection toward different clinical outcomes. Knowledge of pathogenesis will increase the predictive value of antemortem tests to guide appropriate interventions, including identification and treatment of subclinically affected pigs in the early stages of disease, given that this important manifestation reduces pig productivity and contributes to the economic burden of L. intracellularis worldwide.

show abstract

“…To increase the applicability of POCT, various alternative platforms, such as resistive heating, have been employed instead of thermal cyclers. 4,5 However, those methods also require high power and thermal-control complexity, involving temperature programming and proling. For example, a portable PCR device integrated with a thermal system controlled by four thin-lm heaters needs 6.5 W. 4 Another device using a rotary zone thermal cycler, which has four different temperature heat blocks for PCR steps, requires 10 W and a controlled temperature.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 However, those methods also require high power and thermal-control complexity, involving temperature programming and proling. For example, a portable PCR device integrated with a thermal system controlled by four thin-lm heaters needs 6.5 W. 4 Another device using a rotary zone thermal cycler, which has four different temperature heat blocks for PCR steps, requires 10 W and a controlled temperature. 5 An infrared (IR) tungsten lamp requires 50 W. 6 By contrast, isothermal amplication methods can amplify nucleic acids at a constant temperature.…”

Section: Introductionmentioning

confidence: 99%